NCT02392845View on ClinicalTrials.gov

A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Combination of Docetaxel (DTX) and Epirubicin (EPI)

Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02392845 - A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study | Biotech Hunter | Biotech Hunter